Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma. - Wikidata - awgldk - TriplyDB

Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma.

Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma.

http://www.wikidata.org/entity/Q39956327

about

Evaluation of eIF4E expression in an osteosarcoma-specific tissue microarray Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression Tailored cancer immunotherapy using combinations of chemotherapy and a mixture of antibodies against EGF-receptor ligands.Stimulators of mineralization limit the invasive phenotype of human osteosarcoma cells by a mechanism involving impaired invadopodia formation.Correlation between the expression of vegf and survival in osteosarcoma A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study.Clinical development of VEGF signaling pathway inhibitors in childhood solid tumors.Synergistic antiproliferative effect of imatinib and adriamycin in platelet-derived growth factor receptor-expressing osteosarcoma cells.Aptamer-nanoparticle assembly for logic-based detection Synergistic effect of low-dose cucurbitacin B and low-dose methotrexate for treatment of human osteosarcoma.Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma HHLA2, a member of the B7 family, is expressed in human osteosarcoma and is associated with metastases and worse survival Analysis of serum insulin growth factor-1 concentrations in localized osteosarcoma: a children's oncology group study Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma.Emerging drugs for high-grade osteosarcoma.Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature.The prognostic value of elevated vascular endothelial growth factor in patients with osteosarcoma: a meta-analysis and systemic review.Targeted therapy in bone and soft tissue sarcoma in children and adolescents.Current therapeutic strategies and novel approaches in osteosarcoma.The angiogenic asset of soft tissue sarcomas: a new tool to discover new therapeutic targets.Advances in emerging drugs for osteosarcoma.Metastatic osteosarcoma: a challenging multidisciplinary treatment.BYL719, a new α-specific PI3K inhibitor: single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma.IGF signaling pathway analysis of osteosarcomas reveals the prognostic value of pAKT localization.Anti-angiogenesis target therapy for advanced osteosarcoma (Review).Cell surface receptor expression patterns in osteosarcoma.MAPK/ERK Signaling in Osteosarcomas, Ewing Sarcomas and Chondrosarcomas: Therapeutic Implications and Future Directions.Molecular alterations associated with osteosarcoma development.Protein kinase C epsilon and genetic networks in osteosarcoma metastasis.Comment on Xu XW et al.: Prognostic significance of VEGF expression in osteosarcoma: a meta-analysis.Prognostic significance of VEGF expression in osteosarcoma: a meta-analysis.CD49b inhibits osteogenic differentiation and plays an important role in osteosarcoma progression.[Tyrosine kinases in soft tissue tumors].Pazopanib for second recurrence of osteosarcoma in pediatric patients.PDGF/PDGFR effects in osteosarcoma and the "add-on" strategy

P2860

Q24635844-BAEE0513-1DA2-4188-B466-724865479646 Q33520381-07B2682A-AB27-4BDC-91E5-158454FE302E Q34005061-D3C48716-F3CC-461F-8F68-03E41E0B93D8 Q34338502-FE881B4B-8F14-4782-A442-97A6DA32CE78 Q34351720-E2A51B82-7EE0-42A1-9CFA-559BFDD84BE8 Q34628840-B5250BA0-E6DD-4C6F-9271-47865AB61DEF Q35599819-9A6E8BAF-3C46-46ED-997E-F36EF6E603F1 Q35904214-759C0587-A4B0-458D-9D4C-75D201057698 Q36354404-F6A42477-F778-4F38-9B1A-725ACC79D6FF Q37047540-BAB69E13-1220-4E4C-A781-F917B26A78A9 Q37125088-5947120C-D4B5-4F72-9B01-4F9B5E1A9387 Q37181493-A0906C0A-3D18-4DCF-8EC1-D3A2B33AF31B Q37624249-814D1B6D-C687-4B6E-9592-2A5A67028A2F Q37624276-A1DD7A6F-B4F0-4BDD-A982-6B998D28F2D8 Q37778400-75E63999-C5E8-4CB2-B0C1-926AB66D0C31 Q37860966-311D5FFD-16E2-41B0-9B01-CF963352E253 Q37978530-27971A99-E82D-49D5-843D-B496C23F2995 Q37981129-64EA5F29-BFE1-4E69-924F-BAF2C63D9348 Q38161735-31574AFF-0AA0-4FF5-9CB0-1DED7E58B214 Q38252537-36B03637-CB37-4969-9513-4A1564D2AF24 Q38506118-4072457C-C9C3-48C4-B6E5-FBDA0E369FA1 Q38783252-885E7E67-C2BC-4893-86D0-D67660426715 Q38981617-DDD9D6AF-B035-4BCF-BC7E-D94C54A3CF3E Q39326887-FE0FA0B6-C7FB-4031-8759-1DF81A260A3B Q39401628-ACFC5EF1-75DE-455D-9320-03CD67C0B32E Q39507656-00625094-C1C9-4C06-9017-1C4815955BB1 Q39618772-7D46E56D-42C1-450B-9CFB-EB7E408803BD Q42070262-4D29D502-3B35-4210-8091-EAF4FB0DFF9C Q42265507-90D92857-9371-4116-AE4A-C34B0B5A8684 Q45003260-473C47A0-343F-4C0C-9BB6-805A8D269A8C Q45259300-D1D22993-B66F-402F-A602-BC5774AB2D9E Q46835072-AEAB8DA4-01E4-4994-B0B9-2E9040C55D6D Q54324690-F9AF51F1-7039-4FED-B3CE-F9079F10EBE0 Q54998059-568C475E-A6CD-404D-8CCA-6D93E9F3CA86 Q58803894-4D0991B6-36CC-4345-BD69-3221DD69DA51

P2860

Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma.

http://www.wikidata.org/entity/Q39956327

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh

2009年學術文章

@zh-hant

name

Correlation between clinical o ...... ression in osteogenic sarcoma.

@en

Correlation between clinical o ...... ression in osteogenic sarcoma.

@nl

type

label

Correlation between clinical o ...... ression in osteogenic sarcoma.

@en

Correlation between clinical o ...... ression in osteogenic sarcoma.

@nl

prefLabel

Correlation between clinical o ...... ression in osteogenic sarcoma.

@en

Correlation between clinical o ...... ression in osteogenic sarcoma.

@nl

P1433

Q39956327-839BE8BE-4483-4361-A1E8-90FC8F364BF9

P1476

Q39956327-6D63E7DE-2F01-472B-AAC8-836422C3FE29

P2093

Q39956327-051D3CDA-F138-4950-A311-C62740F81C8B

Q39956327-0E90AB80-E43A-4F94-8E62-5813BC6FBAC6

Q39956327-477FCACD-A538-4FB9-B794-C1CF2F35A3E3

Q39956327-6F237FEF-CF70-4E55-BC98-9F2E76FA346C

Q39956327-A1FCA765-6E0E-4B86-900E-758B026A5A87

Q39956327-ACF1638D-43AC-4EA1-BE4E-C2EC6F06553B

Q39956327-B46CBE55-8BF0-49C6-AEA9-2ADB95DF7750

Q39956327-C5CF5B87-74C6-4A43-BA82-02698A0C4E23

P2860

Q39956327-E2AFE71C-FB69-40E2-9724-1C1918592ADC

Q39956327-FA1E4F80-6637-460A-8088-11DC9FE5CB81

P304

Q39956327-E0DD3F9D-B835-4443-B19D-B77C618D912B

P31

Q39956327-E75E33CD-F38C-493E-BF76-ED55329F255D

P356

Q39956327-7A8B58B9-EEE8-4613-B303-AC6E5FF32278

P407

Q39956327-D6C4689E-4501-4215-AC8F-371364E36559

P433

Q39956327-031E21D1-BCB7-4CEB-8F64-E1B42ED5AE7E

P478

Q39956327-4F9BCFF2-4660-4B18-A3AA-9D86ED984FD9

P50

Q39956327-2D7CBC8A-A147-48F2-9D40-FA66F4A33D32

Q39956327-AF732B40-1FD9-46EF-9EDB-035E82051FCB

P577

Q39956327-20DC1EA3-0F43-4B88-9BF1-3F7946060DE2

P5875

Q39956327-E9F7DB95-1287-4AF6-9495-149577F73FCA

P698

Q39956327-FB1D2D44-A09C-4625-ACC2-0950AC222099

P356

P1433

P1476

Correlation between clinical o ...... ression in osteogenic sarcoma.

@en

P2093

Ayesha Abdeen

http://www.w3.org/2001/XMLSchema#string

Chand Khanna

http://www.w3.org/2001/XMLSchema#string

Dan Wang

http://www.w3.org/2001/XMLSchema#string

John H Healey

http://www.w3.org/2001/XMLSchema#string

Karen Moody

http://www.w3.org/2001/XMLSchema#string

Mimi Kim

http://www.w3.org/2001/XMLSchema#string

Richard Gorlick

http://www.w3.org/2001/XMLSchema#string

Tanasa S Osborne

http://www.w3.org/2001/XMLSchema#string

P2860

Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.

Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution

P304

5243-5250

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.24562

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

115

http://www.w3.org/2001/XMLSchema#string

P50

Stephen M. Hewitt

P577

2009-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26732003

http://www.w3.org/2001/XMLSchema#string

P698

19670450

http://www.w3.org/2001/XMLSchema#string